SØG - mellem flere end 8 millioner bøger:
Viser: Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology
Søgbar e-bog
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology Vital Source e-bog
Witold Lasek og Radoslaw Zagozdzon
(2016)
Springer Nature
679,00 kr.
Leveres umiddelbart efter køb
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology Vital Source e-bog
Witold Lasek og Radoslaw Zagozdzon
(2016)
Springer Nature
441,00 kr.
Leveres umiddelbart efter køb
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology Vital Source e-bog
Witold Lasek og Radoslaw Zagozdzon
(2016)
Springer Nature
339,00 kr.
Leveres umiddelbart efter køb
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology
Witold Lasek, Radoslaw Zagozdzon og Marek Jakobisiak
(2016)
Sprog: Engelsk
Springer International Publishing AG
646,00 kr.
ikke på lager, Bestil nu og få den leveret
om ca. 10 hverdage
om ca. 10 hverdage
Detaljer om varen
- Vital Source searchable e-book (Fixed pages)
- Udgiver: Springer Nature (September 2016)
- Forfattere: Witold Lasek og Radoslaw Zagozdzon
- ISBN: 9783319469065
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).
Licens varighed:
Bookshelf online: 5 år fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Bookshelf online: 5 år fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- Vital Source 180 day rentals (fixed pages)
- Udgiver: Springer Nature (September 2016)
- Forfattere: Witold Lasek og Radoslaw Zagozdzon
- ISBN: 9783319469065R180
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).
Licens varighed:
Bookshelf online: 180 dage fra købsdato.
Bookshelf appen: 180 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Bookshelf online: 180 dage fra købsdato.
Bookshelf appen: 180 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- Vital Source 90 day rentals (fixed pages)
- Udgiver: Springer Nature (September 2016)
- Forfattere: Witold Lasek og Radoslaw Zagozdzon
- ISBN: 9783319469065R90
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).
Licens varighed:
Bookshelf online: 90 dage fra købsdato.
Bookshelf appen: 90 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Bookshelf online: 90 dage fra købsdato.
Bookshelf appen: 90 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 2 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- Paperback
- Udgiver: Springer International Publishing AG (Oktober 2016)
- Forfattere: Witold Lasek, Radoslaw Zagozdzon og Marek Jakobisiak
- ISBN: 9783319469058
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).
Biology of IL-12 -
1.1.Molecular structure of IL-12,-1.2.IL-12 receptor, -1.3.Regulation of IL-12 expression,-
1.4.Role of IL-12 in antitumor immunity,-
1.5.References 2 Antitumor effects of IL-12 in preclinical studies -
2.1.IL-12 in a single-agent therapy and in the combined treatment of animal tumors,-2.2.Experimental IL-12-based gene therapy,-2.3.References 3 Clinical trials with IL-12 in cancer immunotherapy -
3.1.Early clinical studies,-3.2.Cutaneous T cell lymphoma (CTCL),-3.3.Hodgkin's and non-Hodgkin's lymphoma,-3.4.Kaposi's sarcoma,-3.5.Trends in IL-12-based approaches in oncology,-3.6.References.
1.1.Molecular structure of IL-12,-1.2.IL-12 receptor, -1.3.Regulation of IL-12 expression,-
1.4.Role of IL-12 in antitumor immunity,-
1.5.References 2 Antitumor effects of IL-12 in preclinical studies -
2.1.IL-12 in a single-agent therapy and in the combined treatment of animal tumors,-2.2.Experimental IL-12-based gene therapy,-2.3.References 3 Clinical trials with IL-12 in cancer immunotherapy -
3.1.Early clinical studies,-3.2.Cutaneous T cell lymphoma (CTCL),-3.3.Hodgkin's and non-Hodgkin's lymphoma,-3.4.Kaposi's sarcoma,-3.5.Trends in IL-12-based approaches in oncology,-3.6.References.
De oplyste priser er inkl. moms
Butikker og åbningstid
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Polyteknisk Boghandel og Forlag A/S - Anker Engelundsvej 1 - 2800 Lyngby
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927